TMO
Thermo Fisher Scientific
$464.01
▼ 0.1%Updated Today 7:15 PM ET
▲ Up 18.4% over the last 12 months
Market Cap
$172.66B
P/E
25.41x
Forward P/E (est.)
23.82x
ROE
13.2%
Revenue Growth
5.4%
EPS Growth
6.7%
Profit Margin
15.2%
FCF Yield
5.1%
Debt / Equity
0.74x
ROIC
6.0%
Interest Coverage
5.63x
Current Ratio
1.53x
Dividend Yield
0.4%
Implied Growth (rev. DCF)
5.2%
Rating Score
49/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what TMO's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. TMO trades near $464.01, below its 50-day average ($477.65) and 200-day average ($525.93). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 39 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. TMO's is $14.21 (~3.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month TMO found buyers near $438.66 (support) and sellers near $499.00 (resistance); its 52-week range is $385.46–$643.99. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Thermo Fisher Scientific (TMO) is a large-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $172.66B.
In its latest reported year it generated about $44.56B in revenue and $6.70B in net profit.
Our model rates TMO Neutral (49/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
3.2%
Revenue moved from $39.21B in 2021 to $44.56B in 2025, a 3.2% compound annual growth rate. The most recent year grew a steady 5.4% year over year. Slower, mature growth is common for established businesses.
Gross Margin
40.9%
Operating Margin
17.4%
Net Margin
15.0%
ROE
13.2%
Thermo Fisher Scientific keeps about 15.2% of each sales dollar as net profit, with a 40.9% gross margin and 17.4% operating margin. Return on equity is 13.2% and return on invested capital about 6.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$42.95B
Net Debt
$39.69B
Net Debt / EBITDA
5.12x
Debt / Equity
0.74x
Leverage: debt-to-equity is 0.7x, and operating profit covers interest about 5.6x, with a current ratio of 1.5x. That is a moderate, manageable debt load for most businesses. It carries roughly $42.95B of total debt against $3.25B of cash.
Operating CF
$7.82B
Free Cash Flow
$6.29B
FCF Margin
14.1%
In the latest year Thermo Fisher Scientific produced about $7.82B of operating cash flow and $6.29B of free cash flow after capital spending. That is a free-cash-flow yield of about 5.1% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
25.41x
P/S
3.97x
P/B
4.01x
EV / EBITDA
21.51x
TMO trades at 25.4x trailing earnings (about 23.8x on estimated forward earnings), 4.0x sales, and 4.0x book value. Reverse-engineering today's price implies the market expects roughly 5.2% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How TMO stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), TMO ranks #37 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (25.4x P/E vs. 25.4x median) with a lower return on equity (13.2% vs. 14.9%) and slower revenue growth (5.4% vs. 7.9%).
P/E vs sector
25.4x
median 25.4x
ROE vs sector
13.2%
median 14.9%
Growth vs sector
5.4%
median 7.9%
Sector rank
#37
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$344.30 – $573.83
vs. $464.01 today · expected CAGR -6% – 4%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $46.78B | $49.12B | $51.58B | $54.16B | $56.87B |
| Net income | $7.02B | $7.37B | $7.74B | $8.12B | $8.53B |
| EPS | $18.88 | $19.83 | $20.82 | $21.86 | $22.95 |
| Share price (low) | $283.25 | $297.42 | $312.29 | $327.90 | $344.30 |
| Share price (high) | $472.09 | $495.70 | $520.48 | $546.50 | $573.83 |
| CAGR (low–high) | -39% / 2% | -20% / 3% | -12% / 4% | -8% / 4% | -6% / 4% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for TMO:
- High net margins (15.2%) point to pricing power or efficiency.
- Healthy free-cash-flow yield (~5.1%) funds buybacks and dividends.
The case against TMO:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Thermo Fisher Scientific is a large-cap health care business growing at a mature pace, with solid profitability, and a heavier debt load to watch. It trades at 25.4x earnings, which our model scores Neutral (49/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.